In migraine with previous treatment failures, eptinezumab safely reduced migraine days at 1 to 12 wk
- PMID: 36191321
- DOI: 10.7326/J22-0077
In migraine with previous treatment failures, eptinezumab safely reduced migraine days at 1 to 12 wk
Abstract
Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21:597-607. 35716692.
Comment on
-
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.Lancet Neurol. 2022 Jul;21(7):597-607. doi: 10.1016/S1474-4422(22)00185-5. Lancet Neurol. 2022. PMID: 35716692 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical